Friday, July 10, 2026

pharma · Prurigo Nodularis · Vitiligo

Incyte

Incyte is a pharma organization headquartered in Wilmington, USA. Primary therapeutic focus areas include Prurigo Nodularis, Vitiligo, Hidradenitis Suppurativa, Chronic Graft-Versus-Host Disease, chronic graft-versus-hos

1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
Employees
3,381
Programs
53
Drugs
61
Patents
0
Clinical program

INCB 00928-104

Phase 2 · other · Anaemia associated with myelofibrosis

INCB 00928-104 for Anaemia associated with myelofibrosis is a Phase 2 program (other) at Incyte with 1 ClinicalTrials.gov record(s).

← All Incyte projects Phase 2 other active

Internal code INCB 00928-104

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Incyte
Phase
Phase 2
Modality
other
Indication
Anaemia associated with myelofibrosis
Status
active
Trials
1